Gilead's acquisition valued at over $3 billion.
Tubulis specializes in cancer therapies.
The deal aims to strengthen Gilead's position in oncology.
Gilead Acquires Tubulis for Over $3 Billion to Boost Oncology Portfolio
In a significant move to enhance its oncology pipeline, Gilead has announced the acquisition of Tubulis, a German biotech firm, for more than $3 billion.